Open AccessLenvatinib Long-Term Responses in Refractory Thyroid Cancer: Our Mono-Institutional Real-Life Experience with the Multidisciplinary Approach and Review of Literature
Author(s) -
Nerina Denaro,
Adele Latina,
Flora Cesario,
F. Bramardi,
Corrado Lauro,
Giorgio Borretta,
Marco Merlano
Publication year - 2019
Publication title -
oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.987
H-Index - 98
eISSN - 1423-0232
pISSN - 0030-2414
DOI - 10.1159/000501691
Subject(s) - lenvatinib , medicine , cabozantinib , discontinuation , everolimus , adverse effect , refractory (planetary science) , renal cell carcinoma , oncology , thyroid cancer , kidney cancer , cancer , physics , astrobiology
Lenvatinib (LEN) is a multikinase inhibitor with antiangiogenic properties recently approved in radioactive iodine-refractory differentiated thyroid cancer, hepatocellular carcinoma, and renal cell carcinoma in combination with everolimus. LEN-treated patients frequently have adverse events (AEs) that generally require such dose modifications, including drug discontinuation. Hypertension, diarrhea, weight loss, proteinuria, fatigue, and palmar-plantar erythrodysesthesia are reported among the most frequent AEs, often leading to discontinuations or dose modifications. This paper reports a case series focusing on the role of the immediate multidisciplinary approach to manage AEs.